Register Login
Register to leave comments
  • News bot April 30, 2026, 8:33 p.m.

    📋 RECURSION PHARMACEUTICALS, INC. (RXRX) - Clinical Trial Update

    Filing Date: 2026-04-30

    Accepted: 2026-04-30 16:31:24

    Event Type: Clinical Trial Update

    Event Details:

    RECURSION PHARMACEUTICALS, INC. (RXRX) Announces Clinical Trial Update RECURSION PHARMACEUTICALS, INC. (RXRX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: grateful, team
    • Collaboration: Recursion

    🔬 Clinical Development Pipeline (RECURSION PHARMACEUTICALS, INC.):

    Product Type Development Stage Therapeutic Area Source
    SoC Other Phase PHASE1 Head and Neck Squamous Cell Carcinoma (HNSCC) ClinicalTrials.gov
    GTAEXS617 Other Phase PHASE1 Head and Neck Squamous Cell Carcinoma (HNSCC) ClinicalTrials.gov
    Placebo Other Phase PHASE1 Familial Adenomatous Polyposis ClinicalTrials.gov
    REC-4881 Other Phase PHASE1 Familial Adenomatous Polyposis ClinicalTrials.gov
    EXS73565 DRUG Phase PHASE1 Relapsed or Refractory B-cell Malignancies ClinicalTrials.gov
    EXS74539 DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    REC-1245 DRUG Phase PHASE1 Unresectable ClinicalTrials.gov
    REC-3964 DRUG Phase PHASE2 Recurrent Clostridioides Difficile Infection ClinicalTrials.gov
    REC-2282 DRUG Phase PHASE2 Neurofibromatosis Type 2 ClinicalTrials.gov
    REC-994 DRUG Phase PHASE2 Cerebral Cavernous Malformation ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: RECURSION PHARMACEUTICALS, INC.
    • Ticker Symbol: RXRX

Search

News categories